Makers Laboratories (506919.BO) Osake Kurssi

Makers Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India, operating within the Health Care sector. The company has a workforce of 121 employees and went public on July 13, 1993. It manufactures and markets pharmaceutical products, focusing on various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). Additionally, Makers Laboratories offers Inspira retail packs, covering categories like acid regulatory, anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics, anti-nauseants, anti-fungal, anti-hypertensives, and other health-related products. The Experia bulk packs division provides bulk pharmaceutical products including amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and similar items. The company's website is https://www.makerslabs.com/. Makers Laboratories Ltd is listed on the Bombay Stock Exchange under the ticker 506919.BO and holds the ISIN INE987A01010. The company operates through the pharmaceuticals segment, emphasizing general health therapeutic areas. It does not disclose specific financial figures or additional details beyond its product lines and operational structure.